Biglycan and related therapeutics and methods of use

Details Biglycan and related therapeutics and methods of use Biglycan and related therapeutics and methods of use

2005-03-08

2005-03-08

Ulm, John (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C435S004000, C435S007200, C435S007210, C436S063000, C436S501000

Reexamination Certificate

active

06864236

ABSTRACT:
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

REFERENCES:
patent: 0686397 (1995-04-01), None
patent: WO 9310808 (1993-10-01), None
Chan, Yiu-mo et al. Molecular Organization of Sarcoglycan Complex in Mouse Myotubes in Culture.J. Cell Bio.143, 2033-2044 (Dec. 28, 1998).
Crosbie, Rachelle H. et al. Membrane Targeting and Stabilizatoin of Sarcospan is Mediated by the Saroglycan Subcomplex.J. Cell. Biol.145, 159-165 (Apr. 5, 1999).
Ervasti, James M. & Campbell, Kevin P. A Role for the Dystrophin-Glycoprotein Complex as a Transmembrane Linker between Laminin and Actin.J. Cell Biol.122, 809-823 (Aug. 1993).
Ferri, R. T. et al. A Role for Biglycan in Agrin-Induced Postsynaptic Differentiation.Society for Neuroscience Abstracts26 (2000) [Abstract Only].
Gee, Stephen H. et al. Dystroglycan-a, a Dystrophin-Associated Glycoprotein, is a Functional Agrin Receptor.Cell77, 675-686 (Jun. 3, 1994).
Hoch, Werner. Formation of the Neuromuscular Junction: Agrin and its unusual receptors.Eur. J. Biochem. 265, 1-10(1999).
Holt, Kathleen H. et al. Functional Rescue of the Sarcoglycan Complex in the BIO 14.6 Hamster Using S-Sarcoglycan Gene Transfer.Mol. Cell1, 841-848 (May 1998).
Jarvelainen, Hannu T. et al. Differential Expression of Small Chondroitin/Dermatan Sulfate Proteoglycans, PG-I/Biglycan and PG-II/Decorin, by Vascular Smooth Muscle and Endothelial Cells in Culture.J. Biol. Chem.266, 23274-23281 (Dec. 5, 1991).
Junghans, Ulrich et al. Purification of a Meningeal Cell-derived Chondroitin Sulphate Proteoglycan with Neurotrophic Activity for Brain Neurons and its Identification as Biglycan.Euro. J. Neurosci.7, 2341-2350 (1995).
Sakamoto, Aiji et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, S-sarcoglycan, in hamster. An animal model of disrupted dystrophin-associated glycoprotein complex.PNAS94, 13873-13878 (Dec. 1997).
Tomoyasu, Hiroshi et al. Identification of haemopoietic biglycan in hyperplastic thymus associated with myasthenia gravis,J. Neuroimmunology, 89, 59-63 (1998).
Winder, Steven J. The complexitites of dystroglycan.Trends in Biochem. Sci.26, 118-124 (2001).

Affiliated with

Also associated with

Rating

Biglycan and related therapeutics and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biglycan and related therapeutics and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biglycan and related therapeutics and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3392014